Dose‐related modulation of the synaptic proteome after short‐term treatment with XPro1595 for Alzheimer’s disease
Parris Pope, Ian Pike, CJ Barnum, RJ Tesi · 2025
Read Dose‐related modulation of the synaptic proteome after short‐term treatment with XPro1595 for Alzheimer’s disease by Parris Pope, Ian Pike, CJ Barnum, RJ Tesi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712735.txt.
Description
Parris Pope and co-authors test a drug for Alzheimer disease in a 2025 study. The drug, XPro1595, is a lab built protein that soaks up just the harmful form of a swelling signal. Past work marks that signal as a driver of brain harm.
Twenty patients got one of three doses each week for twelve weeks. The team read the full protein mix in spinal fluid before and after. Some protein groups shifted in step with dose, which hints the drug hit its target. Brain tissue from past donors served as a check set. The small early trial sets up larger tests of dose and effect.
Catalog record
| CREATOR | Parris Pope, Ian Pike, CJ Barnum, RJ Tesi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |